Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 10/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HINT1 | P49773 | 4/20 | 0.33 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049954 | 0.82 | HINT1 (0.51) | STING1HPGDHINT1GSK3ARPS6KA3 | |
| SCHEMBL19050071 | 0.81 | STING1 (0.41) | STING1HPGDHINT1 | |
| SCHEMBL19050067 | 0.78 | STING1 (0.38) | STING1HPGDHINT1 | |
| SCHEMBL12154680 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL1737049 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL12300437 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL6726990 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL12150649 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL16198948 | 0.75 | PNP (0.48) | STING1HPGD | |
| SCHEMBL24487813 | 0.74 | SLC28A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | STING1 503/4885PRMT5 800/4885WDR77 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.